Access the full text.
Sign up today, get DeepDyve free for 14 days.
K. Eagle, M. Lim, O. Dabbous, K. Pieper, R. Goldberg, F. Werf, S. Goodman, C. Granger, P. Steg, J. Gore, A. Budaj, Á. Avezum, M. Flather, K. Fox, Grace Investigators (2004)
A validated prediction model for all forms of acute coronary syndrome:estimating the risk of 6-month postdischarge death in an international registryJAMA, 291
P. Gurbel, M. Roe, J. Jakubowski, S. Shah, D. Erlinge, S. Goodman, K. Huber, M. Chan, J. Cornel, U. Tantry, E. Ohman (2012)
Translational platelet research in patients with coronary artery disease: What are the major knowledge gaps?Thrombosis and Haemostasis, 108
J. Jakubowski, K. Winters, H. Naganuma, L. Wallentin (2007)
Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile.Cardiovascular drug reviews, 25 4
J. Silvain, G. Cayla, J. Hulot, J. Finzi, M. Kerneis, S. O’Connor, A. Bellemain‐Appaix, O. Barthelemy, F. Beygui, J. Collet, G. Montalescot (2012)
High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study.European heart journal, 33 10
P. Gurbel, U. Tantry (2012)
Platelet Function Testing and Genotyping Improve Outcome in Patients Treated With Antithrombotic AgentsCirculation, 125
S. Wiviott, D. Trenk, A. Frelinger, M. O’Donoghue, F. Neumann, A. Michelson, D. Angiolillo, H. Hod, G. Montalescot, Debra Miller, J. Jakubowski, Richard Cairns, S. Murphy, C. Mccabe, E. Antman, E. Braunwald (2007)
Prasugrel Compared With High Loading– and Maintenance–Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation–Thrombolysis in Myocardial Infarction 44 TrialCirculation, 116
D. Erlinge, J. Berg, D. Foley, D. Angiolillo, H. Wagner, Patricia Brown, Chunmei Zhou, Junxiang Luo, J. Jakubowski, B. Moser, D. Small, T. Bergmeijer, S. James, K. Winters (2012)
Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial.Journal of the American College of Cardiology, 60 20
G. Campo, G. Parrinello, P. Ferraresi, B. Lunghi, M. Tebaldi, M. Miccoli, J. Marchesini, F. Bernardi, R. Ferrari, M. Valgimigli (2011)
Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome.Journal of the American College of Cardiology, 57 25
PA Gurbel, US Tantry (2012)
Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents? platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents., 125
GW Stone
Assessment of dual antiplatelet therapy with drug-eluting stents: a large-scale, prospective, multicenter registry examining the relationship between platelet responsiveness and stent thrombosis after DES implantation (ADAPT-DES).
M. Roe, P. Armstrong, K. Fox, H. White, D. Prabhakaran, S. Goodman, J. Cornel, Deepak Bhatt, P. Clemmensen, F. Martinez, D. Ardissino, J. Nicolau, W. Boden, P. Gurbel, W. Rużyłło, A. Dalby, Darren Mcguire, J. Leiva-Pons, A. Parkhomenko, S. Gottlieb, G. Topacio, C. Hamm, G. Pavlides, A. Goudev, A. Oto, C. Tseng, B. Merkely, V. Gašparović, R. Corbalán, M. Cinteză, R. McLendon, K. Winters, E. Brown, Y. Lokhnygina, P. Aylward, K. Huber, J. Hochman, E. Ohman (2012)
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.The New England journal of medicine, 367 14
D. Trenk, G. Stone, M. Gawaz, A. Kastrati, D. Angiolillo, U. Müller, G. Richardt, J. Jakubowski, F. Neumann (2012)
A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent PlacemJournal of the American College of Cardiology, 59 24
M. Price, P. Berger, P. Teirstein, J. Tanguay, D. Angiolillo, D. Spriggs, S. Puri, M. Robbins, K. Garratt, O. Bertrand, M. Stillabower, Joseph Aragon, D. Kandzari, Curtiss Stinis, Michael Lee, S. Manoukian, C. Cannon, N. Schork, E. Topol (2011)
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.JAMA, 305 11
D Erlinge, PB Brown, KJ Winters (2012)
Prasugrel 5 mg in the very elderly is non-inferior to prasugrel 10mg in non-elderly patients: the GENERATIONS trial, a pharmacodynamic (PD) study in stable CAD patients., 33
D. Aradi, A. Komócsi, A. Vorobcsuk, O. Rideg, M. Tőkés-Füzesi, T. Magyarlaki, I. Horváth, V. Serebruany (2010)
Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis.American heart journal, 160 3
P. Gurbel, K. Bliden, K. Hayes, U. Tantry (2004)
Platelet activation in myocardial ischemic syndromesExpert Review of Cardiovascular Therapy, 2
C. Granger, J. Alexander, M. Hanna, Jessie Wang, Puneet Mohan, J. Lawrence, E. Hylek, J. Ansell, L. Wallentin (2012)
Effects of community-based general practitioners-led care for 12,864 patients with hypertension: study of cardiovascular risk intervention - hypertension (SCRI-HTN) in ChinaEuropean Heart Journal
D Trenk, GW Stone, M Gawaz (2012)
A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study., 59
D Erlinge, J Ten Berg, D Foley
Reduction in Platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial [published online October 17, 2012].
ORIGINAL CONTRIBUTION ONLINE FIRST Platelet Function During Extended Prasugrel and Clopidogrel Therapy for Patients With ACS Treated Without Revascularization The TRILOGY ACS Platelet Function Substudy Context The relationship of platelet function testing measurements with outcomes Paul A. Gurbel, MD in patients with acute coronary syndromes (ACS) initially managed medically without David Erlinge, MD revascularization is unknown. E. Magnus Ohman, MB, ChB Objective To characterize the differences and evaluate clinical outcomes associated with platelet reactivity among patients with ACS treated with clopidogrel or prasugrel. Benjamin Neely, MS Design, Setting, and Patients Patients with medically managed unstable angina Megan Neely, PhD or non–ST-segment elevation myocardial infarction were enrolled in the TRILOGY ACS Shaun G. Goodman, MD, MSc trial (2008 to 2011) comparing clopidogrel vs prasugrel. Of 9326 participants, 27.5% were included in a platelet function substudy: 1286 treated with prasugrel and 1278 Kurt Huber, MD treated with clopidogrel. Mark Y. Chan, MD Interventions Aspirin with either prasugrel (10 or 5 mg/d) or clopidogrel (75 mg/ Jan H. Cornel, MD d); those 75 years or older and younger than 75 years but who weighed less than 60 kg received a 5-mg prasugrel maintenance dose. Eileen Brown, PhD Chunmei Zhou, MS Main Outcome
JAMA – American Medical Association
Published: Nov 7, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.